TCW Group Inc. lessened its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 650,760 shares of the biopharmaceutical company’s stock after selling 57,361 shares during the period. TCW Group Inc.’s holdings in Alexion Pharmaceuticals were worth $77,824,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently modified their holdings of the stock. Virtus Fund Advisers LLC increased its position in Alexion Pharmaceuticals by 10.6% in the 4th quarter. Virtus Fund Advisers LLC now owns 68,801 shares of the biopharmaceutical company’s stock valued at $8,228,000 after acquiring an additional 6,608 shares during the period. UBS Asset Management Americas Inc. increased its position in Alexion Pharmaceuticals by 10.3% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock valued at $223,818,000 after acquiring an additional 174,606 shares during the period. Schroder Investment Management Group increased its position in Alexion Pharmaceuticals by 14.0% in the 4th quarter. Schroder Investment Management Group now owns 33,939 shares of the biopharmaceutical company’s stock valued at $4,059,000 after acquiring an additional 4,163 shares during the period. Advanced Asset Management Advisors Inc acquired a new position in Alexion Pharmaceuticals in the 4th quarter valued at about $837,000. Finally, Rhumbline Advisers increased its position in Alexion Pharmaceuticals by 3.9% in the 4th quarter. Rhumbline Advisers now owns 403,489 shares of the biopharmaceutical company’s stock valued at $48,253,000 after acquiring an additional 15,174 shares during the period. Hedge funds and other institutional investors own 95.38% of the company’s stock.
Several equities analysts recently issued reports on ALXN shares. Piper Jaffray Companies restated an “overweight” rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Stifel Nicolaus lowered their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th. Royal Bank of Canada lifted their price objective on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective on the stock in a report on Tuesday, October 31st. Finally, TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $152.77.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $120.47 on Monday. The company has a market capitalization of $26,705.96, a P/E ratio of 61.46, a PEG ratio of 1.12 and a beta of 1.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.26 EPS. research analysts expect that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current fiscal year.
In other news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the sale, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the sale, the senior vice president now directly owns 32,635 shares in the company, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. Insiders have sold a total of 28,930 shares of company stock worth $3,378,199 in the last three months. Corporate insiders own 4.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://ledgergazette.com/2018/02/19/alexion-pharmaceuticals-inc-alxn-shares-sold-by-tcw-group-inc-2.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.